Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRd-Elotuzumab in Relapsed/Refractory Multiple Myeloma
NCT03361306Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2018
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Started Jan 2018; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03361306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361306.